• Ogdie A, de Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T, Kwok K, Wang C, Hsu M-A, Maniccia A. Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Abstract 0221. • Pohlmeyer C, Cui Z-H, Han P, Clarke AS, Jones RM, Mollova N, Mikaelian I, Zaboli S, Shauf A, Di Paolo JA. Monotherapy with filgotinib, a JAK1-selective inhibitor, reduces disease severity and alters immune cell subsets in the NZB/W F1 murine model of Lupus. Abstract 0484. • Pope J, Michaud K, Emery P, Zhu B, Gaich C, DeLozier A, Zhang X, Dickson C, Smolen JS. Reduction in fatigue and pain are associated with improved work productivity in patients with RA. Abstract 0240. • Ritchlin C, Giles J, Ogdie A, Gomez-Reino J, Stockert L, Young P, Wang C, Romero AB, Kudlacz E. Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of Phase 3 studies. Abstract 0317. • Smolen JS, Cohen S, Emery P, Rigby W, Tanaka Y, Zhang Y, Friedman A, Othman AA, Camp HS, Pangan AL. Upadacitinib as monotherapy: a Phase 3 randomized controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. Abstract 0035. • Soriano ER, Madariaga H, Castañeda O, Citera G, Schneeberger EE, Cardiel MH, Hendrikx T, Graham D, Shi H, Ponce de Leon D. Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes. Abstract 0099. • Strand V, Mysler E, Moots RJ, Wallenstein G, DeMasi R, Gruben D, Soma K, Iikuni N, Fleischmann R. Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a Phase 3B/4 randomised trial. Abstract 0256. • Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: results from select-next. Abstract 0254. • Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J. Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND Phase III trial). Abstract 0255. • Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Correia AP, Otawa S, Lopez-Romero P, de La Torre I, Rooney T, Smolen JS. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Abstract 0253. • Takeuchi T, Smolen JS, Fleischmann R, Iikuni N, Fan H, Soma K, Akylbekova E, Hirose T. Clinical and functional response to tofacitinib and adalimumab in patients with rheumatoid arthritis: probability plot analysis of results from the ORAL strategy trial. Abstract 0252. • Tamura N, Kuwana M, Atsumi T, Takei S, Harigai M, Fujii T, Matsuno H, Mimori T, Momohara S, Yamamoto K, Nomura K, Endo Y, Sugiyama N, Hirose T, Morishima Y, Yoshii N, Takagi M. Post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data. Abstract 0495. • Tanaka Y, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othman AA, Pangan AL, Kitamura S, Matsuda N, Meerwein S, Kameda H. A Phase 2B/3 randomized, placebo-controlled, double-blind study of upadacitinib, a selective JAK1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic DMARDS. Abstract 0257. • van Vollenhoven R, Dore R, Chen K, Camp HS, Enejosa J, Shaw T, Suboticki JL, Hall S. Impact of 12 weeks of upadacitinib treatment on individual and composite disease measures in patients with rheumatoid arthritis and inadequate response to conventional synthetic or biologic DMARDS. Abstract 0244. • Vieira-Sousa E, Eusébio M, Ávila-Ribeiro P, Khmelinskii N, Machado AR, Rocha TM, Bernardes M, Santos- Faria D, Silva JL, Santos H, Miguel C, Carvalho P, Costa T, Teixeira L, Meirinhos T, Nero P, Santos MJ. Tumor necrosis factor inhibitors persistence in psoriatic arthritis patients. Abstract 0920. • Wiesenhutter C. Initiating tofacitinib in a treat to target strategy for rheumatoid arthritis leads to blunted multibiomarker disease activity scores as compared to anti-tumour necrosis factor agents. Abstract 0089. • Youssef P, Marcal B, Button P, Truman M, Bird P, Griffiths H, Roberts L, Tymms K, Littlejohn G. Reasons for bDMARD cessation and subsequent persistence of second line treatment in a large real world rheumatoid arthritis registry. Abstract 0165. • Yu CK-L. Clinical and musculoskeletal ultrasound assessment of therapeutic response to tofacitinib in patients with rheumatoid arthritis: real-world clinical experience from a single center in Hong Kong. Abstract 0210. • Zengin B, Inanç N, Akar S, Can G, Dalkilic E, Tufan A, Senel S, Koca SS, Capar S, Tugsal HY, Birlik M, Akkoc N, Onen F. Similar efficacy of tofacitinib on disease activity in rheumatoid arthritis patients with and without previous biologicals; results from the TURKBIO registry. Abstract 0482.
Enhancing knowledge of the clinical importance of cytokine signalling The Cytokine Signalling Forum www.cytokinesignalling.com <strong>EULAR</strong> <strong>2018</strong> Conference Highlights
Change language